NCT03149445 - Co-administration of Tesofensine/Metoprolol in Subjects With Prader-Willi Syndrome (PWS) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 30, 2017

Primary Completion Date

July 22, 2019

Study Completion Date

July 22, 2019

Conditions

Confirmed Genetic Diagnosis of Prader-Willi Syndrome

Interventions

DRUG

Tesofensine/Metoprolol

Study medication will be administered for 91 days.

DRUG

Placebos

Study medication will be administered for 91 days.

Trial Locations (2)

Motol University Hospital, Prague

Semmelweis University, Budapest